BALDRY MARK (Chief Commercial Officer) sold 18.7% of their position (11.13K shares) of X4 PHARMACEUTICALS, INC on the open market
Open‑market sale worth $6.5K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 10/8/2024ACC: 0001628280-24-042544
Officer· Chief Commercial Officer
Since Nov 2022
+23.82K
Net shares
Net buyer
$6.5K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
34.95K acquired · 11.13K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+34.95K
Price / share
—
Trade value
—
% of position
141.5%
10/4/2024
24.69K→59.64K
Common Stock
Direct
Shares
−11.13K
Price / share
$0.58
Trade value
$6.51K
% of position
18.7%
10/7/2024
59.64K→48.51K
Total
Net shares
+23.82K
Net value
-$6.51K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/4/2024 | A · Award | +34.95K | — | — | 141.5% | 24.69K | 59.64K |
| Common Stock Direct | 10/7/2024 | S · Sale | −11.13K | $0.58 | $6.51K | 18.7% | 59.64K | 48.51K |
| Total | +23.82K | -$6.51K | ||||||
Derivative Transactions0
No derivative transactions reported